181 related articles for article (PubMed ID: 37887301)
1. CEP55 as a Promising Immune Intervention Marker to Regulate Tumor Progression: A Pan-Cancer Analysis with Experimental Verification.
Wang G; Chen B; Su Y; Qu N; Zhou D; Zhou W
Cells; 2023 Oct; 12(20):. PubMed ID: 37887301
[TBL] [Abstract][Full Text] [Related]
2. MiR-144 suppresses proliferation, invasion, and migration of breast cancer cells through inhibiting CEP55.
Yin Y; Cai J; Meng F; Sui C; Jiang Y
Cancer Biol Ther; 2018 Apr; 19(4):306-315. PubMed ID: 29561704
[TBL] [Abstract][Full Text] [Related]
3. Lentivirus-mediated knockdown of CEP55 suppresses cell proliferation of breast cancer cells.
Wang Y; Jin T; Dai X; Xu J
Biosci Trends; 2016 Feb; 10(1):67-73. PubMed ID: 26902787
[TBL] [Abstract][Full Text] [Related]
4. Centrosomal protein 55 activates NF-κB signalling and promotes pancreatic cancer cells aggressiveness.
Peng T; Zhou W; Guo F; Wu HS; Wang CY; Wang L; Yang ZY
Sci Rep; 2017 Jul; 7(1):5925. PubMed ID: 28724890
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of centrosomal protein 55 is associated with unfavorable prognosis and tumor invasion in epithelial ovarian carcinoma.
Zhang W; Niu C; He W; Hou T; Sun X; Xu L; Zhang Y
Tumour Biol; 2016 May; 37(5):6239-54. PubMed ID: 26615423
[TBL] [Abstract][Full Text] [Related]
6. Cancer-testis antigen CEP55 serves as a prognostic biomarker and is correlated with immune infiltration and immunotherapy efficacy in pan-cancer.
Xie X; Liang H; Jiangting W; Wang Y; Ma X; Tan Z; Cheng L; Luo Z; Wang T
Front Mol Biosci; 2023; 10():1198557. PubMed ID: 37484531
[No Abstract] [Full Text] [Related]
7. CEP55 is a determinant of cell fate during perturbed mitosis in breast cancer.
Kalimutho M; Sinha D; Jeffery J; Nones K; Srihari S; Fernando WC; Duijf PH; Vennin C; Raninga P; Nanayakkara D; Mittal D; Saunus JM; Lakhani SR; López JA; Spring KJ; Timpson P; Gabrielli B; Waddell N; Khanna KK
EMBO Mol Med; 2018 Sep; 10(9):. PubMed ID: 30108112
[TBL] [Abstract][Full Text] [Related]
8. CEP55: an immune-related predictive and prognostic molecular biomarker for multiple cancers.
Li GS; Zhang W; Huang WY; He RQ; Huang ZG; Gan XY; Yang Z; Dang YW; Kong JL; Zhou HF; Chen G
BMC Pulm Med; 2023 May; 23(1):166. PubMed ID: 37173675
[TBL] [Abstract][Full Text] [Related]
9. CEP55 promotes epithelial-mesenchymal transition in renal cell carcinoma through PI3K/AKT/mTOR pathway.
Chen H; Zhu D; Zheng Z; Cai Y; Chen Z; Xie W
Clin Transl Oncol; 2019 Jul; 21(7):939-949. PubMed ID: 30607788
[TBL] [Abstract][Full Text] [Related]
10. A Comprehensive Pan-Cancer Analysis Identifies CEP55 as a Potential Oncogene and Novel Therapeutic Target.
Zaki MSA; Eldeen MA; Abdulsahib WK; Shati AA; Alqahtani YA; Al-Qahtani SM; Otifi HM; Asiri A; Hassan HM; Emam Mohammed Ahmed H; Dawood SA; Negm A; Eid RA
Diagnostics (Basel); 2023 May; 13(9):. PubMed ID: 37175004
[TBL] [Abstract][Full Text] [Related]
11. CEP55 contributes to human gastric carcinoma by regulating cell proliferation.
Tao J; Zhi X; Tian Y; Li Z; Zhu Y; Wang W; Xie K; Tang J; Zhang X; Wang L; Xu Z
Tumour Biol; 2014 May; 35(5):4389-99. PubMed ID: 24390615
[TBL] [Abstract][Full Text] [Related]
12. CEP55 3'-UTR promotes epithelial-mesenchymal transition and enhances tumorigenicity of bladder cancer cells by acting as a ceRNA regulating miR-497-5p.
Yang C; Yang Y; Wang W; Zhou W; Zhang X; Xiao Y; Zhang H
Cell Oncol (Dordr); 2022 Dec; 45(6):1217-1236. PubMed ID: 36374443
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of CEP55 Predicts Dismal Prognosis in Patients with Liver Cancer.
Yang L; He Y; Zhang Z; Wang W
Biomed Res Int; 2020; 2020():4139320. PubMed ID: 32337246
[TBL] [Abstract][Full Text] [Related]
14. CEP55 promotes the proliferation and invasion of tumour cells via the AKT signalling pathway in osteosarcoma.
Xu L; Xia C; Sheng F; Sun Q; Xiong J; Wang S
Carcinogenesis; 2018 Apr; 39(4):623-631. PubMed ID: 29579156
[TBL] [Abstract][Full Text] [Related]
15. α-catenin interaction with YAP/FoxM1/TEAD-induced CEP55 supports liver cancer cell migration.
Tang Y; Thiess L; Weiler SME; Tóth M; Rose F; Merker S; Ruppert T; Schirmacher P; Breuhahn K
Cell Commun Signal; 2023 Jun; 21(1):162. PubMed ID: 37381005
[TBL] [Abstract][Full Text] [Related]
16. CEP55 predicts the poor prognosis and promotes tumorigenesis in endometrial cancer by regulating the Foxo1 signaling.
Zhang X; Xu Q; Li E; Shi T; Chen H
Mol Cell Biochem; 2023 Jul; 478(7):1561-1571. PubMed ID: 36434144
[TBL] [Abstract][Full Text] [Related]
17. SPAG5 interacts with CEP55 and exerts oncogenic activities via PI3K/AKT pathway in hepatocellular carcinoma.
Yang YF; Zhang MF; Tian QH; Fu J; Yang X; Zhang CZ; Yang H
Mol Cancer; 2018 Aug; 17(1):117. PubMed ID: 30089483
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-144-3p inhibits cell proliferation and promotes apoptosis in castration-resistant prostate cancer by targeting CEP55.
You B; Zhang KC
Eur Rev Med Pharmacol Sci; 2018 Nov; 22(22):7660-7670. PubMed ID: 30536308
[TBL] [Abstract][Full Text] [Related]
19. Expression and clinical significance of centrosomal protein 55 in T-cell lymphoma.
Xu Y; Zhou X; Li Y; Zhang Y; Wang X
J Cancer Res Ther; 2018 Jan; 14(1):94-98. PubMed ID: 29516967
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of miR-144-3p exacerbates non-small cell lung cancer progression by targeting CEP55.
Li M; Liu Y; Jiang X; Hang Y; Wang H; Liu H; Chen Z; Xiao Y
Acta Biochim Biophys Sin (Shanghai); 2021 Oct; 53(10):1398-1407. PubMed ID: 34435195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
